NGL Fine-Chem Limited Total Assets
NGL Fine-Chem Limited total assets. Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) holds total assets worth Rs5.45 Billion INR (≈ $58.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NGLFINE stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of NGL Fine-Chem Limited (2009–2026)
Total assets of NGL Fine-Chem Limited from 2009 to 2026. This chart illustrates how NGL Fine-Chem Limited's total assets have evolved over time, based on quarterly financial data. See today's stock price for NGL Fine-Chem Limited for real-time trading data and today's change.
NGL Fine-Chem Limited - Asset Composition Analysis
NGL Fine-Chem Limited Total Assets Breakdown (March 2026)
NGL Fine-Chem Limited total assets breakdown as of March 2026. NGL Fine-Chem Limited's total assets of Rs5.45 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.9% |
| Accounts Receivable | Rs1.31 Billion | 24.0% |
| Inventory | Rs702.80 Million | 12.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs2.82 Million | 0.1% |
| Goodwill | Rs1.53 Million | 0.0% |
Asset Composition Trend (2009–2026)
This chart illustrates how NGL Fine-Chem Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of NGL Fine-Chem Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NGL Fine-Chem Limited's current assets represent 50.7% of total assets in 2026, a decrease from 66.0% in 2009.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2026, down from 5.4% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 24.0% of total assets.
NGL Fine-Chem Limited Competitors by Total Assets
Key competitors of NGL Fine-Chem Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
NGL Fine-Chem Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.84 | 1.98 | 2.95 |
| Quick Ratio | 1.37 | 1.55 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.26 Billion | Rs1.16 Billion | Rs823.85 Million |
NGL Fine-Chem Limited - Advanced Valuation Insights
This section examines the relationship between NGL Fine-Chem Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.39 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 25.9% |
| Total Assets | Rs5.45 Billion |
| Market Capitalization | $169.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values NGL Fine-Chem Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NGL Fine-Chem Limited's assets grew by 25.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NGL Fine-Chem Limited (2009–2026)
The table below shows the annual total assets of NGL Fine-Chem Limited from 2009 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs5.45 Billion ≈ $58.99 Million |
+25.87% |
| 2025-03-31 | Rs4.33 Billion ≈ $46.87 Million |
+21.90% |
| 2024-03-31 | Rs3.56 Billion ≈ $38.45 Million |
+23.85% |
| 2023-03-31 | Rs2.87 Billion ≈ $31.05 Million |
+3.67% |
| 2022-03-31 | Rs2.77 Billion ≈ $29.95 Million |
+33.29% |
| 2021-03-31 | Rs2.08 Billion ≈ $22.47 Million |
+35.25% |
| 2020-03-31 | Rs1.54 Billion ≈ $16.61 Million |
+8.04% |
| 2019-03-31 | Rs1.42 Billion ≈ $15.38 Million |
+9.98% |
| 2018-03-31 | Rs1.29 Billion ≈ $13.98 Million |
+27.69% |
| 2017-03-31 | Rs1.01 Billion ≈ $10.95 Million |
+30.63% |
| 2016-03-31 | Rs775.06 Million ≈ $8.38 Million |
+16.52% |
| 2015-03-31 | Rs665.17 Million ≈ $7.19 Million |
+19.11% |
| 2014-03-31 | Rs558.46 Million ≈ $6.04 Million |
+17.83% |
| 2013-03-31 | Rs473.96 Million ≈ $5.13 Million |
+27.44% |
| 2012-03-31 | Rs371.90 Million ≈ $4.02 Million |
+13.20% |
| 2011-03-31 | Rs328.53 Million ≈ $3.55 Million |
+29.53% |
| 2010-03-31 | Rs253.64 Million ≈ $2.74 Million |
+24.59% |
| 2009-03-31 | Rs203.57 Million ≈ $2.20 Million |
-- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more